This shows that the origin of DMBA/TPA-induced BCC is not determined by the chemical treatment but, rather, by the compartment of the genetically targeted cell type, and thus, the CD4Cre-deleter most likely targets K5+ basal cells of HF-near IFE. Here, KRT5 is linked to skin basal cell carcinoma.